Clinical trials in the midst of COVID-19

Clinical trials are an essential part of getting new treatments from lab to patient but during the COVID-19 pandemic, trials for treatments outside of COVID-19 had been heavily disrupted.

However, in light of all this immediate disruption there have been claims that the swift action taken to produce a vaccine and the adoption of technology could set a positive precedent for the future of clinical trial research.

In the latest paper from our European life sciences group, we focus on the implementation of clinical trials in Europe. We address the issues affecting ongoing trials; including data management, compliance with protocols, measures to be taken by sponsors, and the recommendations and regulations imposed by the authorities. We also look at the challenges surrounding the opening of new trials, including trials for COVID-19 treatments and vaccines.

Click below to download the full paper:

 

A version of this paper was originally published by Applied Clinical Trials